The incidence rate of opportunistic
secondary infections through invasive fungi has been observed to be 14.5% to 27% in the SARS CoV pandemic during the year 2003. However, the incidence of SARS CoV-2 is accompanied by a substantial rise in secondary
opportunistic infections like
mucormycosis (black fungus), mainly in the immunocompromised individuals and diabetic patients taking
steroids. Substantial rates of
COVID-19 cases with
mucormycosis were reported in India and other parts of the world. Previous research reports delineated the ability of Mucorales to invade the various tissues like lungs, brain, and sinus through the
GRP78, and subsequently, this
infection could invoke crusting,
edema, and
necrosis of the brain parenchyma, ptosis,
proptosis, and vision loss due to intraorbital and intracranial complications. Similarities of these pathophysiological complications with already existing diseases are causing clinicians to face several challenges in order to diagnose and treat this disease effectively at the early stage. This minireview depicts the
mucormycosis-induced immune and pathophysiological alterations in
COVID-19 patients comorbid with diabetes and immunosuppression and also reported the various clinical manifestations, the therapeutic modalities, and the failures of anti-
fungal vaccines. Therefore, the emerging
mucormycosis in
COVID-19 patients needs rapid investigation and selective optimization of the effective therapeutic modalities, including antifungal
vaccines, to minimize the mortality rate.